Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas - Wikidata - awgldk - TriplyDB

Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas

Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas

http://www.wikidata.org/entity/Q30384396

about

Coming of age: the artificial pancreas for type 1 diabetes Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement Progress of artificial pancreas devices towards clinical use: the first outpatient studies A Review of Safety and Design Requirements of the Artificial Pancreas.Big Data Technologies: New Opportunities for Diabetes Management Future of Automated Insulin Delivery Systems.Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes Heart rate informed artificial pancreas system enhances glycemic control during exercise in adolescents with T1D.The Artificial Pancreas in 2016: A Digital Treatment Ecosystem for Diabetes.Multinational Home Use of Closed-Loop Control Is Safe and Effective.Identification of Main Factors Explaining Glucose Dynamics During and Immediately After Moderate Exercise in Patients With Type 1 Diabetes.Adjustment of Open-Loop Settings to Improve Closed-Loop Results in Type 1 Diabetes: A Multicenter Randomized Trial.Sensitivity of the Predictive Hypoglycemia Minimizer System to the Algorithm Aggressiveness Factor Hypoglycemia Reduction and Accuracy of Continuous Glucose Monitoring Engineering control into medicine Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes.Assessing sensor accuracy for non-adjunct use of continuous glucose monitoring Switched LPV Glucose Control in Type 1 Diabetes.Using uncertain data from body-worn sensors to gain insight into type 1 diabetes.Mobile technology and the digitization of healthcare.Unsupervised home use of an overnight closed-loop system over 3-4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes.Impact of new technologies on diabetes care.Accuracy of Continuous Glucose Monitoring During Three Closed-Loop Home Studies Under Free-Living Conditions.Home Use of an Artificial Beta Cell in Type 1 Diabetes Improved Accuracy of Continuous Glucose Monitoring Systems in Pediatric Patients with Diabetes Mellitus: Results from Two Studies.Metabolic Control With the Bio-inspired Artificial Pancreas in Adults With Type 1 Diabetes: A 24-Hour Randomized Controlled Crossover Study.Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.Combining glucose monitoring and insulin delivery into a single device: current progress and ongoing challenges of the artificial pancreas Randomized Crossover Comparison of Personalized MPC and PID Control Algorithms for the Artificial Pancreas.Artificial Pancreas Device Systems for the Closed-Loop Control of Type 1 Diabetes: What Systems Are in Development?Hybrid Closed-Loop Insulin Delivery in Type 1 Diabetes During Supervised Outpatient Conditions.Reducing Glucose Variability Due to Meals and Postprandial Exercise in T1DM Using Switched LPV Control: In Silico Studies.Physical activity and type 1 diabetes: time for a rewire?An artificial pancreas for automated blood glucose control in patients with Type 1 diabetes.Nonadjunctive Use of Continuous Glucose Monitoring for Diabetes Treatment Decisions.Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.Enhanced Model Predictive Control (eMPC) Strategy for Automated Glucose Control.The challenges of achieving postprandial glucose control using closed-loop systems in patients with type 1 diabetes.The artificial pancreas: evaluating risk of hypoglycaemia following errors that can be expected with prolonged at-home use.Periodic zone-MPC with asymmetric costs for outpatient-ready safety of an artificial pancreas to treat type 1 diabetes

P2860

Q26745886-3FD18FA2-739C-49FA-AC00-589B77566562 Q26769878-B4260BFA-05C5-409B-9CD6-C1BF4FC0BEB4 Q26825236-94617D5F-FA38-47D3-B549-A1085D0FEF48 Q28066687-8078CC87-132B-4F17-B920-A490CCB66CD1 Q28606802-79540AFD-3C14-49CD-8ECF-34550201D160 Q30252197-0BE48DDB-9630-4257-B1DB-B122AF1E3D66 Q30274891-293937B3-107D-45CF-BC91-50F1B67DA0DC Q30275746-A39FA81C-DB2D-420C-AF5D-55A398E7B179 Q30276534-CCD40206-BEAF-4DBC-93F2-66EF59DAE640 Q30276768-788DFD1B-6D2C-4130-8452-E450886449EC Q30278498-883C694A-E885-4531-8732-FBB28B0D4A52 Q30278964-F97B1AD1-68B5-40A8-991E-712AD531D2A2 Q30279078-D7F18FEA-C251-4441-B924-7F29C920D589 Q30299941-48D1A33C-7F7D-464B-A5A7-707DBC51DE10 Q30300786-AD9435F4-1481-44C7-9817-654EBF9C66FD Q30300933-FACFC8A0-C1E9-4700-BA57-87AE8ACE28F0 Q30301250-FEC02891-9D7E-460D-95DF-6D672761F69D Q30352479-BC292A9A-842A-498B-8320-ED9FE8457AE5 Q31125904-5752C4C9-1219-4C58-90EE-BE6FB5BE5FB3 Q33447208-E03C2A5C-9776-41F0-A370-DA05FE07117A Q35877744-E753C210-49BD-46CB-A254-C897FAAE1872 Q35890221-EABD2613-7D03-40B0-98E5-80233A924FBD Q36291620-E08271D3-5AF9-4D80-8F5C-65568D1E5C63 Q36419734-E3E0B2BE-98A8-4C3E-AF21-7E17E9FE28E2 Q36475961-C073656C-40FC-4135-8678-168BA61717B0 Q36638921-F4004AB9-B0DE-4DAF-A560-CF1404B221AF Q36705282-FD74F804-C93C-47D9-9B2D-0FDBB081A3BA Q36815738-25A7FB37-3265-4F8B-8C9C-EE26146E7D06 Q37025582-8D772535-2AFB-483C-A3A5-CF92044EEEA9 Q37288511-84EB1CA8-48B2-412C-AC2D-B27940B9E6B5 Q37288539-8B2B28BB-F696-42C1-B320-FD2C127D689E Q37288560-33723E79-85C2-4513-81CA-8176D94E604C Q38310888-7830FF18-3740-452E-A506-C9D4C2AABCCF Q38498029-E4BBA2A4-4E07-4A03-8304-8FBDB18D1AEF Q38734994-59F70EDF-771C-4432-980F-8283C3CC52F5 Q39071115-B21FB27E-DD55-4A7B-8B93-C05F2360CA0D Q39110148-ECEE6F93-880D-4CEB-AD65-256E6745A03F Q39413453-F8A08B48-8B10-4810-9B19-9D675FDF9A69 Q40995624-336277F9-0B3A-4952-84E1-2068D907F2C4 Q41207382-AD17CD5E-9914-4BF0-879B-C111A49F8982

P2860

Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas

http://www.wikidata.org/entity/Q30384396

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Safety of outpatient closed-lo ...... a wearable artificial pancreas

@ast

Safety of outpatient closed-lo ...... a wearable artificial pancreas

@en

type

label

Safety of outpatient closed-lo ...... a wearable artificial pancreas

@ast

Safety of outpatient closed-lo ...... a wearable artificial pancreas

@en

prefLabel

Safety of outpatient closed-lo ...... a wearable artificial pancreas

@ast

Safety of outpatient closed-lo ...... a wearable artificial pancreas

@en

P1433

Q30384396-7CF45328-35F4-46B8-B36F-5EE9AA577B98

P1476

Q30384396-2430E5EC-E211-4AFE-88CA-6176B6B51B0F

P2093

Q30384396-0F63A7B3-AE71-48DE-900B-47709F91562B

Q30384396-23588877-9AEF-4D14-9F7A-39DFBC868F8E

Q30384396-24FD41FC-3FEF-425E-8BCD-007A6388AB45

Q30384396-4AC395BB-837B-4A81-B89C-E5021A2A8E8D

Q30384396-5144EC6B-B9B6-4EBA-8B08-4CCF2D3A26F3

Q30384396-51DFC2A9-B684-43A0-B3C5-8587843D2E42

Q30384396-589F61A7-954C-4D76-A746-CD6F125DDBA7

Q30384396-59DA4DE4-37E1-456F-905E-33B126F12FA8

Q30384396-8365F148-4154-4745-854E-66D6F188C6EB

Q30384396-859F9A70-C152-43BB-85C0-78FDC2C38F4E

P2860

Q30384396-029A35DF-67D5-4104-B06F-14660F97A612

Q30384396-1F974EE3-0A37-4C0F-91FC-A17E07744F98

Q30384396-2006E4B5-F206-4E60-8C89-1E9B7D6FBA86

Q30384396-2AC0AC7B-4CBD-4784-85A5-ED7942302410

Q30384396-2E937A9F-A3FE-4091-B068-4107EA22C8B9

Q30384396-41BC7990-295C-4CE8-BA6C-F8BFE411F7FF

Q30384396-59CF7062-8554-4768-A38E-3C62104FD69D

Q30384396-6B6D9738-2BD1-4A62-8C9C-2617D568202A

Q30384396-7DDCF40C-C09F-4E24-9C4B-78383A5A6414

Q30384396-889A5457-7E02-42E6-AE06-11153667E214

P304

Q30384396-9C3BD8AE-5FF1-4F88-9D6F-F8232293817D

P31

Q30384396-CE3B6125-D543-42A0-B2EB-3BB9031DA0CB

P356

Q30384396-412F6F78-1855-4A66-82F1-794C4336B049

P407

Q30384396-8477D71D-823F-4169-B1EB-A8085974D78C

P433

Q30384396-50F85022-E4DA-40A8-AE24-12000D70651D

P478

Q30384396-E029279F-3664-4524-ADDE-983C696342FE

P50

Q30384396-17D78C3D-3E7C-4406-9C6A-07D556D338E8

Q30384396-2AFCA6E0-B484-47CA-81BD-9B3C7AFD6BCC

Q30384396-5DE5A45A-9543-4ECA-B592-FCC6601EE8AD

Q30384396-C7EA3E82-9327-4293-9282-DC2268C2A771

Q30384396-E34A76D6-EAAF-498E-BA5B-91848CD582C8

Q30384396-F2255A97-8D1F-44E3-B1C6-7687829BCCBB

Q30384396-FC830D90-6160-46E0-93E2-1CE2E4D2126D

P577

Q30384396-6A8F3C2E-9590-4397-97F3-F15F1780780E

P5875

Q30384396-914C0EAE-14DC-4397-BD21-8045849BEC3C

P698

Q30384396-831FFDA5-3AC2-4EA2-B1A7-0990AF330208

P921

Q30384396-8F330432-B172-4F87-A3D7-F6ABC4E4B0AE

Q30384396-FBE958CD-DC3E-40EF-82EA-D4A5715FC1C1

P932

Q30384396-6D209C8B-6B8C-4F1D-9E47-3FB9846FDE5E

P356

P1433

P1476

Safety of outpatient closed-lo ...... a wearable artificial pancreas

@en

P2093

Angelo Avogaro

http://www.w3.org/2001/XMLSchema#string

Anne Farret

http://www.w3.org/2001/XMLSchema#string

Boris P Kovatchev

http://www.w3.org/2001/XMLSchema#string

Daniel R Chernavvsky

http://www.w3.org/2001/XMLSchema#string

Eric Renard

http://www.w3.org/2001/XMLSchema#string

Federico Boscari

http://www.w3.org/2001/XMLSchema#string

Federico Di Palma

http://www.w3.org/2001/XMLSchema#string

Howard C Zisser

http://www.w3.org/2001/XMLSchema#string

Jérôme Place

http://www.w3.org/2001/XMLSchema#string

Lloyd B Mize

http://www.w3.org/2001/XMLSchema#string

P2860

Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies

Modular closed-loop control of diabetes

DiAs web monitoring: a real-time remote monitoring system designed for artificial pancreas outpatient trials

DiAs user interface: a patient-centric interface for mobile artificial pancreas systems

Feasibility of outpatient fully integrated closed-loop control: first studies of wearable artificial pancreas.

Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia

Artificial pancreas: past, present, future

Hypoglycemia prevention via pump attenuation and red-yellow-green "traffic" lights using continuous glucose monitoring and insulin pump data

Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: the Virginia experience

Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index.

P304

1789-1796

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC13-2076

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

Francis J. Doyle III

Simone Del Favero

Claudio Cobelli

Chiara Toffanin

Daniela Bruttomesso

P577

2014-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263100184

http://www.w3.org/2001/XMLSchema#string

P698

24929429

http://www.w3.org/2001/XMLSchema#string

P921

wearable technology

Aizkuņģa dziedzeris

P932

4067397

http://www.w3.org/2001/XMLSchema#string